SCYNEXIS Price to Free Cash Flow Ratio 2013-2024 | SCYX

SCYNEXIS price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as

SCYNEXIS Price to Free Cash Flow Ratio 2013-2024 | SCYX

SCYNEXIS price to free cash flow ratio from 2013 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.3B
Takeda Pharmaceutical (TAK)$46.3B
Merck (MKGAF)$22.8B
Astellas Pharma (ALPMY)$21.5B
Sandoz Group AG (SDZNY)$18B
United Therapeutics (UTHR)$16B
Summit Therapeutics (SMMT)$15.1B
Shionogi (SGIOY)$13.2B
Neurocrine Biosciences (NBIX)$11.6B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$8B
Revolution Medicines (RVMD)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$4.6B
Corcept Therapeutics (CORT)$4.6B
Crinetics Pharmaceuticals (CRNX)$4.1B
Dyne Therapeutics (DYN)$3.4B
PTC Therapeutics (PTCT)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Catalyst Pharmaceuticals (CPRX)$2.3B
Recursion Pharmaceuticals (RXRX)$2B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Ardelyx (ARDX)$1.6B
Harrow (HROW)$1.6B